Evaluation of a New Method for Detecting Cancer by Measuring Glycosidase Activity in Plasma of Patients With Localized Cancer - Pilot Study B-GLUCANCER2

What this Trial Is About

Researchers are investigating a new method to detect and assess cancer by measuring the activity of specific enzymes called glycosidases in patients' blood plasma. This pilot study involves patients with localized breast, lung, or pancreatic cancer, as well as a group of people without cancer, to compare enzyme levels and evaluate the diagnostic potential of this approach. The study is sponsored by Poitiers University Hospital and focuses on early-phase research. Participants with localized cancers will provide two 5ml blood plasma samples, one before surgery and another one month after surgery, to analyze enzyme activity. Healthy volunteers will provide a single 5ml blood plasma sample. The study groups include patients with breast, lung, and pancreatic cancer, alongside a control group with no history of cancer. During the study, researchers will monitor enzyme levels using volatile organic compound-based probes that detect specific glycosidases by identifying ethanol isotopes in the gas phase of blood samples. The primary outcome is to compare enzyme activity before and after surgery in cancer patients versus controls. Secondary outcomes include comparisons among cancer types and over time. Participation involves blood draws and follow-up visits, lasting until one month after surgery for cancer patients or a single visit for healthy volunteers.

B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.